Skip to main content

TFF Pharmaceuticals, Inc.

TFFPDelisted Mar 6, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001733413

TFF Pharmaceuticals, Inc. was delisted on Mar 6, 2025; its insiders filed their last Form 4 on Jul 8, 2024; 23 institutions reported holding it in 13F filings for Q3 2024, worth $1.48M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by TFF Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for TFF Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for TFF Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Rocamboli StephenDirector39,165Jul 8, 20240
Mills Robert SDirector59,145Jul 8, 20240
King Thomas BraxtonDirector1,583Jul 8, 20240
Roberts BrandiDirector23,165Jul 8, 20240
Lee Catherine Chai-zonDirector1,583Jul 8, 20240
Weisman Harlan FPresident and CEO842,095Jul 8, 20240
Coleman Kirk AllenChief Financial Officer45,859Jul 8, 20240
Mikhak ZamanehChief Medical Officer145,184Jul 8, 20240
Patane Michael ADirector–Apr 22, 20240
Carlson Capital, L.P.10% Owner5,064,000IndirectAug 17, 20230
Carlson Clint Duane10% Owner5,064,000IndirectAug 17, 20230
Double Black Diamond Offshore Ltd10% Owner5,064,000IndirectAug 17, 20230
Asgard Investment Corp. II10% Owner5,064,000IndirectAug 17, 20230
Fletcher Aaron G.L.Director143,470Dec 30, 20220
Thurman Randy HDirector0Sep 30, 20220
Mattes Glenn R.President and CEO36,000May 17, 20220
Cano ChristopherChief Operating Officer–Sep 24, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 16, 2021 (view filing)Sep 16Same dayColeman Kirk AllenCFO, Secretary and TreasurerPPurchase+1.00K$7.30+$7.30K+100.0%2.00K after
Sep 16, 2021 (view filing)Sep 16Same dayMattes Glenn R.President and CEOPPurchase+10.0K$7.10+$71.0K+100.0%20.0K after
Apr 4, 2022 (view filing)Apr 4Same dayFletcher Aaron G.L.DirectorPPurchase+542.0K$6.47+$3.50MNew position542.0K after2 lots
May 17, 2022 (view filing)May 161 dayRocamboli StephenDirectorPPurchase+3.00K$4.54+$13.6K+19.1%18.7K after
May 17, 2022 (view filing)May 161 dayMattes Glenn R.President and CEOPPurchase+16.0K$4.78+$76.5K+80.0%36.0K after
May 17, 2022 (view filing)May 16-171 dayColeman Kirk AllenChief Financial OfficerPPurchase+1.68K$4.51+$7.55K+83.8%3.67K after2 lots
May 17, 2022 (view filing)May 161 dayWeisman Harlan FDirectorPPurchase+2.50K$4.74+$11.8K+50.0%7.50K after
May 17, 2022 (view filing)May 16-171 dayFletcher Aaron G.L.DirectorPPurchase+109.6K$4.91+$538.1KNew position109.6K after2 lots
May 20, 2022 (view filing)May 18-202 daysWeisman Harlan FDirectorPPurchase+7.12K$5.37+$38.2K+94.9%14.6K after2 lots
Sep 30, 2022 (view filing)Sep 291 dayThurman Randy HDirectorSSale−40.3K$4.29−$172.7K−100.0%0 after
Nov 23, 2022 (view filing)Nov 221 dayFletcher Aaron G.L.DirectorPPurchase+43.5K$1.15+$50.0K+43.5%143.5K after
Nov 23, 2022 (view filing)Nov 221 dayFletcher Aaron G.L.DirectorPPurchase+21.7K$0.00$0–21.7K afterDerivative
Dec 19, 2022 (view filing)Dec 154 daysWeisman Harlan FPresident and CEOPPurchase+50.0K$1.06+$53.0K+342.1%64.6K after
Mar 13, 2023 (view filing)Mar 103 daysMikhak ZamanehChief Medical OfficerPPurchase+15.0K$0.82+$12.3KNew position15.0K after
Mar 13, 2023 (view filing)Mar 103 daysWeisman Harlan FPresident and CEOPPurchase+150.0K$0.88+$132.0K+232.1%214.6K after
Mar 13, 2023 (view filing)Mar 103 daysColeman Kirk AllenChief Financial OfficerPPurchase+12.0K$0.79+$9.48K+326.5%15.7K after
Mar 13, 2023 (view filing)Mar 103 daysRocamboli StephenDirectorPPurchase+13.0K$0.80+$10.4K+433.3%16.0K after
Aug 15, 2023 (view filing)8:00 AM ETAug 15Same dayMikhak ZamanehChief Medical OfficerPPurchase+120.0K$0.25+$30.0K+800.0%135.0K after
Aug 15, 2023 (view filing)8:00 AM ETAug 15Same dayMills Robert SDirectorPPurchase+40.0K$0.25+$10.0K+250.3%56.0K after
Aug 15, 2023 (view filing)8:00 AM ETAug 15Same dayColeman Kirk AllenChief Financial OfficerPPurchase+20.0K$0.25+$5.00K+127.6%35.7K after
Aug 15, 2023 (view filing)8:00 AM ETAug 15Same dayRoberts BrandiDirectorPPurchase+20.0K$0.25+$5.00KNew position20.0K after
Aug 15, 2023 (view filing)8:00 AM ETAug 15Same dayRocamboli StephenDirectorPPurchase+20.0K$0.25+$5.00K+125.0%36.0K after
Aug 15, 2023 (view filing)8:00 AM ETAug 15Same dayWeisman Harlan FPresident and CEOPPurchase+600.0K$0.25+$150.0K+279.6%814.6K after
Aug 17, 2023 (view filing)5:29 PM ETAug 152 daysCarlson Capital, L.P. and 3 others10% OwnerSSaleCommon Stock, par value $0.001 per share (the "Common Stock"−215.0K$0.4374−$94.0K−4.1%5.07M after
Aug 17, 2023 (view filing)5:29 PM ETAug 161 dayCarlson Capital, L.P. and 3 others10% OwnerSSale−1.00K$0.3916−$391.60.0%5.06M after